| Drug / Therapy | Lorundrostat |
| Indication | Adults with Hypertension and Topline Explore-OSA Tr |
| Decision Type | PDUFA |
| Conditions | Adults with Hypertension and Topline Explore-OSA Tr |
| Interventions | Lorundrostat |
Mineralys Therapeutics, Inc. (MLYS) operates in the Biotech / Pharma sector. The current BiotechSign Score is 27 (Grade: F).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for Lorundrostat by Mineralys Therapeutics, Inc. (MLYS) is scheduled for December 22, 2026. This is the target date for the FDA to make a decision on this application.
Lorundrostat is being developed by Mineralys Therapeutics, Inc. for the treatment of Adults with Hypertension and Topline Explore-OSA Tr. It is under FDA review.
If Lorundrostat receives FDA approval, Mineralys Therapeutics, Inc. (MLYS) would be able to market the drug in the United States for Adults with Hypertension and Topline Explore-OSA Tr. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for MLYS on DilutionWatch at dilutionwatch.com/stock/MLYS.html.
You can view the full BiotechSign company profile for Mineralys Therapeutics, Inc. (MLYS) at biotechsign.com/app/company/MLYS, which includes the BiotechSign Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.